Knight Therapeutics Inc.

Good morning, ladies and gentlemen. My name is Leanne, and I will be your operator today. Welcome to Knight Therapeutics, Inc., 2021 Third Quarter Financial Results Conference Call. Before turning the call over to Samira Zakir, President and CEO of Knight, listeners are reminded that portions of today's discussion may, by their nature, necessarily involve risks and uncertainties. that could cause actual results to differ materially from those contemplated by the forward-looking statements. The company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautious that these assumptions regarding the future events, may of which are beyond the control of the company and its subsidiaries, may ultimately prove to be incorrect. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether a result of new information or future events, except as required by law. We would also like to remind you that questions during today's call will be taken from analysts only. Should there be any further questions, please contact Knight's Investor Relations Department via email to infoatnighttx.com or via phone at 514-678-8930. Again, 514-678-8930. I would like to remind everyone that this call is being recorded today, November 11th, 2021, and would now like to turn the meeting over to your host today, Samira Sakia. Please go ahead, Ms. Sakia.

Thank you, Leanne. Good morning, everyone, and welcome to Knight Therapeutics' third quarter 2021 conference call. I'm joined today on today's call with Amal Khoury, our Chief Business Officer, Arvind Uchina, our Chief Financial Officer, and Jeff Martins, our Global VP of Commercial. I will now walk you through some of our corporate updates. I'm excited to announce that for the second consecutive quarter, Knight achieved record quarterly results despite the ongoing challenges posed by the pandemic. In fact, similar to last quarter, it is due to the pandemic that we have seen an increase in sales of our infectious disease products that were used extensively by physicians to save lives. In addition to the great results, we also had some significant changes to our management team last quarter. Not just myself and Jonathan, but more importantly, the addition of three seasoned executives. Monica Percario joined Knight in September as Global VP of Scientific Affairs with nearly 30 years of experience in the pharmaceutical industry. Monica joins us after a successful career at Sanofi in Brazil, where she had been working since 2008, most recently as head of regulatory and center of expertise for LATAM. At Sanofi, she also participated in the integration of Aventis with Medli, a Brazilian-branded generic pharmaceutical company, and developed a strong expertise in the generics market as well as mature products. Further, she implemented the regional regulatory functions with teams across Latin America. Prior to Sanofi, Monica worked in various regulatory roles at Pharmaca, now a part of Hipera Pharma. During her time there, she created the Pharmacovigilance Department and participated in clinical research studies in the development of biologic products. Daniela Moreno joined us as Global VP of Legal and Compliance with over 20 years of experience in the legal field and the pharma industry. Daniela was previously at Bausch Health, formerly Valiant, in Brazil where she had been working since 2013, most recently as head of legal and compliance for Latin America. At Bausch, she was responsible for all activities carried out by the legal and compliance department in Latin America, including supporting the various business units throughout LATAM, as well as providing transaction support to both legal and corporate teams. In addition, she was responsible for managing all activities related to the legal department and the compliance area. Prior to Bosch, Danielle was at a specialty law firm in Sao Paulo, where she advised clients on mergers and acquisitions, corporate reorganizations, and deal negotiation. Finally, Susan Emblem joined Knight as Global VP of Human Resources. Susan worked for over 20 years at Paladin Labs, where she held a number of leadership roles, including Vice President of HR and Corporate Communications. In fact, Susan played a key role in the integration of Paladin into Endo. Monica and Daniela are based in Sao Paulo, and Susan is based in Montreal. We also continued to execute on expanding our portfolio through our business development activities, and we closed a distribution agreement with Insight for two innovative products. Turning now to the NCIB. We launched 2021 NCIB on July 14th, 2021, and under this NCIB, we can purchase for cancellation up to 10.2M shares. During the quarter, we purchased approximately 3M common shares for an aggregate cash consideration of $15.3M and an average share price of $5.18 per share. Subsequent to the quarter, Knight has purchased an additional 1 million common shares for an aggregate cash consideration of $5.3 million or $5.21 per share. I will now turn the call over to Jeff to provide more details on our product results.

Thank you, Samara. Building on our hard work of 2020, our efforts in 2021 remain focused on executional excellence of our new product launches. Overall, our revenues on a constant currency basis increased by $27.4 million, or 62%, during the quarter versus Q3 last year. The growth in revenues is driven by an incremental demand estimated to be between $9.2 and $11.5 million, primarily due to our infectious disease products that treat invasive fungal infections associated with COVID-19. Of this amount, we estimate that approximately $3.2 million to $4.2 million was not utilized during the nine-month period. In addition, we had an increase of $6 million in net revenues related to the growth of our recently launched products and $9.9 million from the addition of Exelon. Overall, the remainder of the year will remain focused on the execution and acceleration of our launches in our infectious disease portfolio and in our oncology portfolio, as well as for the commercial efforts behind Exelon. With vaccination rates improving in many of our territories, we have started to cautiously return to field. I will now turn the call over to Arvind to go over financial results.